Pulmonx Corporation Share Price & Technical Analysis
LUNG · $1.55 (+0.65%)
Healthcare / Medical Devices
$1.55
+0.65%
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral vent…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
15% return in May, -12% avg return in past 3 year May month.
-25% return in 2026, 1% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -27% | 0% | -13% | 0% | 15% | – | – | – | – | – | – | – | -25% |
| 25 | -16% | 54% | -4% | -28% | -35% | -16% | -31% | -11% | 0% | 25% | -20% | 38% | -45% |
| 24 | 6% | -31% | 2% | -18% | -6% | -10% | 10% | 6% | 24% | -25% | 2% | 10% | -33% |
| 23 | 14% | 23% | 2% | 4% | 4% | 14% | 7% | -24% | 3% | -15% | 24% | 24% | 80% |
| 22 | -25% | 8% | -4% | -4% | -24% | -18% | 15% | 11% | -7% | -21% | -56% | 42% | -83% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Strong
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$53.43M
P/E ratio
—
52W high
$3.88
52W low
$1.13
Volume
3,09,831
Beta
0.18
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Pulmonx Corporation share price today?
- Pulmonx Corporation (LUNG) last traded around $1.55 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does LUNG have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for LUNG. Download the app for real-time alerts.
- How can I analyze Pulmonx Corporation stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.